Literature DB >> 20963563

Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.

Jae Won Hong1, Mi Kyung Lee, Sun Ho Kim, Eun Jig Lee.   

Abstract

The objective of this study was to evaluate characteristics that discriminate prolactinoma from non-functioning pituitary macroadenoma with hyperprolactinemia. We included 117 patients with hyperprolactinemic pituitary macroadenomas. Patients were divided into three groups according to treatment outcomes and pathologic results: (A) prolactinoma that responded to dopamine agonist (DA) treatment (PRDA); (B) prolactinoma requiring surgical treatment (PRS); and (C) non-functioning pituitary adenoma with hyperprolactinemia (NFPAH). Old age, low serum prolactin levels, and extrasellar extension were associated with NFPAH. Most patients with NFPAH had serum prolactin levels less than 100 ng/ml. Visual defects and GH deficiency were more common in patients with NFPAH compared with patients with PRS and PRDA, without difference of tumor size. Galactorrhea and amenorrhea were less frequent in patients with NFPAH than in patients with PRS and PRDA. Post-operative remission of hyperprolactinemia was achieved in 100% of patients with NFPAH and in 72.5% of patients with PRS. DA administration was required in 25.5% of patients with PRS; however, no patients with NFPAH required DA administration. In conclusion, old age, extrasellar tumor extension with relatively low prolactin levels, visual defect, and GH deficiency were considered suggestive of non-functioning pituitary adenoma rather than prolactinoma in hyperprolactinemic pituitary macroadenoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20963563     DOI: 10.1007/s12020-009-9279-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  23 in total

1.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.

Authors:  Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 3.  [Gonadotroph pituitary adenomas].

Authors:  P Chanson
Journal:  Ann Endocrinol (Paris)       Date:  2000-09       Impact factor: 2.478

4.  The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas.

Authors:  B M Arafah; D Prunty; J Ybarra; M L Hlavin; W R Selman
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

Review 5.  Clinically non-functioning pituitary adenoma.

Authors:  Craig A Jaffe
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence.

Authors:  Takumi Abe; Dieter K Lüdecke
Journal:  Surg Neurol       Date:  2002-06

7.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

8.  Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.

Authors:  J Kreutzer; R Buslei; H Wallaschofski; B Hofmann; C Nimsky; R Fahlbusch; M Buchfelder
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

9.  Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome.

Authors:  Maria Licia Calado de Aguiar Ribeiro Cury; Juliana Coutinho Fernandes; Hélio Rubens Machado; Lucila Leico Elias; Ayrton Custódio Moreira; Margaret de Castro
Journal:  Arq Bras Endocrinol Metabol       Date:  2009-02

10.  Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery.

Authors:  M Wichers-Rother; S Hoven; R A Kristof; N Bliesener; B Stoffel-Wagner
Journal:  Exp Clin Endocrinol Diabetes       Date:  2004-06       Impact factor: 2.949

View more
  12 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

2.  Clinical Course of Nonfunctional Pituitary Microadenoma in Children: A Single-Center Experience.

Authors:  Vidhu V Thaker; Adrianne E Lage; Garima Kumari; V Michelle Silvera; Laurie E Cohen
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

3.  Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.

Authors:  Moon Sool Yang; Jae Won Hong; Seung Koo Lee; Eun Jig Lee; Sun Ho Kim
Journal:  J Neurooncol       Date:  2010-11-24       Impact factor: 4.130

4.  Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Authors:  L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

5.  Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Authors:  Yinxing Huang; Chenyu Ding; Fangfang Zhang; Deyong Xiao; Lin Zhao; Shousen Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

6.  The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.

Authors:  Fangfang Zhang; Yinxing Huang; Chenyu Ding; Guoliang Huang; Shousen Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.

Authors:  Tomohiro Kawaguchi; Yoshikazu Ogawa; Teiji Tominaga
Journal:  BMC Res Notes       Date:  2014-08-20

8.  Radiomics Approach for Prediction of Recurrence in Non-Functioning Pituitary Macroadenomas.

Authors:  Yang Zhang; Ching-Chung Ko; Jeon-Hor Chen; Kai-Ting Chang; Tai-Yuan Chen; Sher-Wei Lim; Yu-Kun Tsui; Min-Ying Su
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

9.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08

Review 10.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.